We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The drug candidate SFX-01 is set to be studied in Phase II/III trials to test its efficacy at treating acute respiratory distress syndrome (ARDS), a complication of COVID‐19.